Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating and $200.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE